Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345915 | 0.73 | LPO (0.48) | LPOHTTKMT2AALDH1A1POLB | |
| SCHEMBL27792290 | 0.72 | LPO (0.39) | LPOHTTKMT2AALDH1A1POLB | |
| SCHEMBL6829172 | 0.71 | LPO (0.46) | LPOHTTKMT2AALDH1A1FDPS | |
| SCHEMBL8089847 | 0.71 | LPO (0.41) | LPOHTTKMT2AALDH1A1FDPS | |
| Hydrochloric Acid SCHEMBL28481823 | 0.71 | LPO (0.38) | LPOHTTKMT2AALDH1A1POLB | |
| SCHEMBL8076706 | 0.70 | LPO (0.36) | LPOHTTKMT2AALDH1A1POLB | |
| SCHEMBL7569341 | 0.69 | ALDH1A1 (0.33) | KMT2AALDH1A1POLBTLR8 | |
| SCHEMBL8076693 | 0.68 | LPO (0.43) | LPOHTTKMT2AALDH1A1FDPS | |
| SCHEMBL27769632 | 0.68 | LPO (0.43) | LPOHTTKMT2APOLBFDPS | |
| SCHEMBL8076701 | 0.67 | LPO (0.38) | LPOHTTFDPSL3MBTL1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524961-B2 | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070293679-A1 | Diastereoselective Addition of Lithiated N-Methylimidazole on Sulfinimines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| CN-1487924-A | Farnesyl transferase inhibitors | ���Ͽع�����˾ | 2004-04-07 | — | — | CN | disclosed |
| EP-1339695-A1 | FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002074747-A1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | LPO 4417/4885HTT 4676/4885KMT2A 1830/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | LPO 4193/4885HTT 4628/4885KMT2A 2346/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | LPO 4400/4885HTT 4733/4885KMT2A 2634/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | LPO 4151/4885HTT 4007/4885KMT2A 3687/4885 |
| US-20070293679-A1 | Diastereoselective Addition of Lithiated N-Methylimidazole on Sulfinimines | SULT1A1, SULT1E1, CSNK1A1L | LPO 3929/4885HTT 4648/4885KMT2A 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.